ISTH 2021 Congress
Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » ADAMTS13 and TTP
Theme Navigation
-
Abstract Number: PO156
A Refractory Thrombotic Thrombocytopenic Purpura Case Complicated by Hepatic Sinusoidal Obstruction Syndrome and Successful Management with Defibrotide
-
Abstract Number: OC 53.4
Anti-ADAMTS13 Antibodies in Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)
-
Abstract Number: OC 66.2
Anti-cysteine/Spacer Autoantibodies that Open the Conformation of ADAMTS13 Are a Common Feature of the Autoimmune Response in Immune-mediated Thrombotic Thrombocytopenic Purpura
-
Abstract Number: PB0838
Caplacizumab Rapidly Inhibits VWF-platelet Interaction: Pharmacodynamic Data from Healthy Volunteers and Patients with aTTP
-
Abstract Number: OC 53.2
Children with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) Have a High Incidence of Acute Episodes: Data from the International Hereditary TTP Registry (IHTTP Registry)
-
Abstract Number: PB0850
Delayed Diagnosis of Congenital Thrombotic Thrombocytopenic Purpura Presenting as Recurrent Cryptogenic Strokes
-
Abstract Number: PB0837
Design of a Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment with Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura
-
Abstract Number: OC 66.4
Development of an Easy-to-Use ADAMTS13 Conformation Assay Using Fiber Optic Surface Plasmon Resonance Technology
-
Abstract Number: LPB0079
Evaluation of the Different Platelet-dependent von Willebrand Factor Activity Assays Capacity to Assess the in vivo Inhibitory Effect of Caplacizumab on the VWF-platelet Interaction
-
Abstract Number: PB0845
Evaluation of the Local Tolerability of Recombinant ADAMTS13 Following Subcutaneous Injection in Rabbits
-
Abstract Number: PB0842
HIV is Not the Trigger for HIV-associated TTP
-
Abstract Number: OC 66.1
Investigating the Resistance of ADAMTS13 towards Protease Inhibitors
-
Abstract Number: PB0844
Loss of Diagnostic Utility of D-dimers in Secondary Thrombotic Thrombocytopenic Purpura (TTP) in Patients with Human Immunodeficiency Virus (HIV) Infection
-
Abstract Number: PB0839
Low Plasma ADAMTS13 Activity Contributes to Increased Mortality Rate in Hospitalized Patients with Suspected Heparin-induced Thrombocytopenia
-
Abstract Number: OC 53.1
Major Adverse Cardiovascular Events Are a Major Cause of Morbidity after Recovery from Immune Thrombotic Thrombocytopenic Purpura
-
Abstract Number: PB0836
Melanoma Triggers Severe Thrombotic Thrombocytopenic Purpura and Results in a High Mortality Rate in adamt13-/- Zebrafish
-
Abstract Number: OC 53.3
Outcomes of Subsequent Pregnancy in Women with a History of Immune Thrombotic Thrombocytopenic Purpura
-
Abstract Number: PB0851
PK/PD Modeling and Simulations Highlight the Importance of the Intravenous Loading Dose and Daily Dosing Regimen with Caplacizumab for Patients with aTTP
-
Abstract Number: PB0840
Plasma BioID of ADAMTS13
-
Abstract Number: PO161
Refractory Thrombotic Thrombocytopenic Purpura – A Case Report